1 Bellentani, S & Tiribelli, C (2001) The spectrum of liver disease in the general population: lessons from Dyonisos study. J Hepatol 35, 531–537.
2 Fabrini, E, Sullivan, S & Klein, S (2010) Obesity and non-alcoholic fatty liver disease: biochemical, metabolic and clinical implications. Hepatology 51, 679–689.
3 Marchesini, G, Bugianesi, E, Forlani, G, et al. (2003) Nonalcoholic fatty liver, steatohepatitis and the metabolic syndrome. Hepatology 37, 917–923.
4 Argiles, JM (1989) The obese Zucker rat: a choice for fat metabolism. Pro Lipid Res 28, 33–66.
5 Langcake, P & Pryce, RJ (1974) The production of resveratrol by Vitis vinifera and other members of the Vitaceae as a response to infection or injury. Physiol Plant Phatol 9, 77–86.
6 Signorelli, P & Ghidoni, R (2005) Resveratrol as an anticancer nutrient: molecular basis, open questions and promises. J Nutr Biochem 16, 449–466.
7 Frémont, L (2000) Biological effects of resveratrol. Life Sci 66, 663–673.
8 Goswami, SK & Das, DK (2009) Resveratrol and chemoprevention. Cancer Lett 284, 1–6.
9 Cucciolla, V, Borriello, A, Oliva, A, et al. (2007) Resveratrol: from basic science to the clinic. Cell Cycle 6, 2495–2510.
10 Baur, JA, Pearson, KJ, Price, NL, et al. (2006) Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444, 337–342.
11 Lagouge, M, Argmann, C, Gerhart-Hines, Z, et al. (2006) Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1α. Cell 127, 1109–1122.
12 Zang, M, Xu, S, Maitland-Toolan, A, et al. (2006) Polyphenols stimulate AMP-activated protein kinase, lower lipids and inhibit accelerated atherosclerosis in diabetic LDL receptor-deficient mice. Diabetes 55, 2180–2191.
13 Ahn, J, Cho, I, Kim, S, et al. (2008) Dietary resveratrol alters lipid metabolism-related gene expression of mice on an atherogenic diet. J Hepatol 49, 1019–1028.
14 Shang, J, Chen, LL, Xiao, F, et al. (2008) Resveratrol improves non-alcoholic fatty acid disease by activating AMP-activated protein kinase. Acta Pharmacol Sin 29, 698–706.
15 Macarulla, MT, Alberdi, G, Gómez, S, et al. (2009) Effects of different doses of resveratrol on body fat and serum parameters in rats fed a hypercaloric diet. J Physiol Biochem 65, 369–376.
16 Rivera, L, Morón, R, Zarzuelo, A, et al. (2009) Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats. Biochem Pharmacol 77, 1053–1063.
17 Van der Spuy, W & Pretorius, E (2009) Is the use of resveratrol in the treatment and prevention of obesity premature? Br J Nutr 22, 111–117.
18 Szkudelska, K & Szkudelski, T (2010) Resveratrol, obesity and diabetes. Eur J Pharmacol 635, 1–8.
19 Folch, J, Lees, M & Sloane Stanley, GH (1957) A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 226, 497–509.
20 Brunt, EM, Janney, CG, Di Bisceglie, AM, et al. (1999) Non-alcoholic steatosis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 94, 2467–2474.
21 Zabala, A, Churruca, I, Macarulla, MT, et al. (2004) The trans-10, cis-12 isomer of conjugated linoleic acid reduces hepatic triacylglycerol content without affecting lipogenic enzymes in hamsters. Br J Nutr 92, 383–389.
22 Bieber, L, Abraham, T & Helmrath, T (1972) A rapid spectrophotometric assay for carnitine palmitoyltransferase. Anal Biochem 50, 509–518.
23 Lazarow, P (1981) Assay of peroxisomal beta-oxidation of fatty acids. Methods Enzymol 72, 315–319.
24 Bradford, M (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72, 248–254.
25 Bujanda, L, Hijona, E, Larzabal, M, et al. (2008) Resveratrol inhibits non-alcoholic fatty liver disease in rats. BMC Gastroenterol 8, 40–48.
26 Kleiner, DE, Brunt, EM, Natta, MV, et al. (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41, 1313–1321.
27 Bertelli, AA, Giovannini, L, Stradi, R, et al. (1998) Evaluation of kinetic parameters of natural phytoalexin in resveratrol orally administered in wine to rats. Drugs Exp Clin Res 24, 51–55.
28 Zabala, A, Churruca, I, Macarulla, MT, et al. (2004) The trans-10, cis-12 isomer of conjugated linoleic acid reduces heaptic triacylglycerol content without affecting lipogenic enzymes in hamsters. Br J Nutr 92, 282–289.
29 Szkudelska, K & Szkudelski, T (2010) Resveratrol, obesity and diabetes. Eur J Pharmacol 635, 1–8.
30 Katsurada, A, Iritani, N, Fukuda, H, et al. (1990) Effects of nutrients and hormones on transcriptional and post-transcriptional regulation of fatty acid synthase in rat liver. Eur J Biochem 190, 427–433.
31 Kim, K, Park, S & Kim, Y (1992) Regulation of fatty acid synthase at transcriptional and post-transcriptional levels in rat liver. Yonsei Med J 33, 199–208.
32 Munday, MR (2002) Regulation of mammalian acetyl CoA carboxylase. Biochem Soc Trans 30, 1059–1064.
33 Tong, L (2005) Acetyl-Coenzyme A carboxylase: crucial metabolic enzyme and attractive target for drug discovery. Cell Mol Life Sci 62, 1784–1803.
34 Howitz, KT, Bittrman, KJ, Cohen, HY, et al. (2003) Small molecule activator of sirtuins extends Saccharomyces cerevisiae life span. Nature 425, 191–196.
35 Borra, MT, Smith, BC & Denu, JM (2005) Mechanism of human SIRT1 activation by resveratrol. J Biol Chem 280, 17187–17195.
36 Medina-Gómez, G, Gray, S & Vidal-Puig, A (2007) Adipogenesis and lipotoxicity; role of peroxisome proliferator-activated receptor γ (PPARγ) and PPARγ-coactivator-1 (PGC1). Public Health Nutr 10, 1132–1137.
37 Stefanovic-Racic, M, Perdomo, G, Mantell, BS, et al. (2008) A moderate increase in carnitine palmitoyltransferase 1a activity is sufficient to substantially reduce hepatic triglyceride levels. Am J Physiol 294, E969–E977.
38 Xu, A, Wang, Y, Keshaw, H, et al. (2003) The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 112, 91–100.
39 Raz, I, Eldor, R, Cernea, S, et al. (2005) Diabetes: insulin resistance and derangements in lipid metabolism. Cure through intervention in fat transport and storage. Diabetes Metabol Res Rev 21, 3–14.
40 Pruneta, V, Autran, D, Ponsin, G, et al. (2001) Ex vivo measurement of lipoprotein lipase-dependent very low density lipoprotein (VLDL)-triglyceride hydrolysis in human VLDL: an alternative to the postheparin assay of lipoprotein lipase activity? J Clin Endocrinol Metab 86, 797–803.
41 Duvnjak, M, Lerotic, I, Barsic, N, et al. (2007) Pathogenesis and management issues for non-alcoholic fatty liver disease. World J Gastroenterol 13, 4539–4550.
42 Spolarics, Z & Meyenhofer, M (2000) Augmented resistance to oxidative stress in fatty rat livers induced by a short-term sucrose-rich diet. Biochim Biophys Acta 1487, 190–200.
43 Albano, E, Mottaran, E, Vidali, M, et al. (2005) Immune response towards lipid peroxidation products as a predictor of progression of non-alcoholic fatty liver disease to advanced fibrosis. Gut 54, 987–993.
44 Faine, LA, Rodrigues, HG, Galhardi, CM, et al. (2006) Effects of olive oil and its minor constituents on serum lipids, oxidative stress and energy metabolism in cardiac muscle. Can J Physiol Pharmacol 84, 239–245.
45 Valdecantos, MP, Pérez-Matute, P & Martínez, JA (2009) Obesity and oxidative stress: role of antioxidant supplementation. Rev Invest Clin 61, 127–139.
46 Yu, BP (1994) Cellular defenses against damage reactive oxygen species. Physiol Rev 74, 139–162.
47 Thong-Ngam, D, Samuhasaneeto, S, Kulaputana, O, et al. (2007) N-acetylcysteine attenuates oxidative stress and liver pathology in rats with non-alcoholic steatohepatitis. J Gastroenterol 14, 5127–5132.
48 Cho, IJ, Ahn, JY, Kim, S, et al. (2008) Resveratrol attenuates the expression of HMG-CoA reductase mRNA in hamsters. Biochem Biophys Res Comm 367, 190–194.
49 Sbarra, V, Ristorcelli, E, Le Pétit-Thévenin, J, et al. (2005) In vitro polyphenol effects on activity, expression and secretion of pancreatic bile salt-dependent lipase. Biochim Biophys Acta 1736, 67–76.
50 Miura, D, Miura, Y & Yagasaki, K (2003) Hypolipidemic action of dietary resveratrol, a phytoalexin in grapes and red wine, in hepatoma-bearing rats. Life Sci 73, 1393–1400.
51 Noll, C, Hamalet, J, Ducros, V, et al. (2009) Resveratrol supplementation worsen the dysregulation of genes involved in hepatic lipid homeostasis observed in hyperhomocysteinemic mice. Food Chem Toxicol 47, 230–236.